These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32438972)

  • 1. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer.
    Lim D; Do Y; Kwon BS; Chang W; Lee MS; Kim J; Cho JG
    BMB Rep; 2020 Jun; 53(6):291-298. PubMed ID: 32438972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
    Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
    Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
    Zheng N; Zhang S; Wu W; Zhang N; Wang J
    Pharmacol Res; 2021 Apr; 166():105507. PubMed ID: 33610718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.
    Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
    Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer.
    Li S; Zhang Q; Zhou L; Guan Y; Chen S; Zhang Y; Han X
    Biomed Pharmacother; 2017 Dec; 96():982-992. PubMed ID: 29208325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasculogenic mimicry in carcinogenesis and clinical applications.
    Luo Q; Wang J; Zhao W; Peng Z; Liu X; Li B; Zhang H; Shan B; Zhang C; Duan C
    J Hematol Oncol; 2020 Mar; 13(1):19. PubMed ID: 32169087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.
    Ayala-Domínguez L; Olmedo-Nieva L; Muñoz-Bello JO; Contreras-Paredes A; Manzo-Merino J; Martínez-Ramírez I; Lizano M
    Front Oncol; 2019; 9():998. PubMed ID: 31612116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling pathways in tumor vasculogenic mimicry.
    Vartanian AA
    Biochemistry (Mosc); 2012 Sep; 77(9):1044-55. PubMed ID: 23157265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs.
    Hu H; Ma T; Liu N; Hong H; Yu L; Lyu D; Meng X; Wang B; Jiang X
    Int Immunopharmacol; 2022 Oct; 111():109116. PubMed ID: 35969899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry.
    Wang JY; Sun T; Zhao XL; Zhang SW; Zhang DF; Gu Q; Wang XH; Zhao N; Qie S; Sun BC
    Cancer Biol Ther; 2008 May; 7(5):758-66. PubMed ID: 18376140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system.
    Qu B; Guo L; Ma J; Lv Y
    Med Hypotheses; 2010 Feb; 74(2):360-1. PubMed ID: 19744799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes.
    Han H; Du L; Cao Z; Zhang B; Zhou Q
    Eur J Pharmacol; 2018 Jan; 818():593-603. PubMed ID: 29162433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.
    Wei X; Chen Y; Jiang X; Peng M; Liu Y; Mo Y; Ren D; Hua Y; Yu B; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Xiong W; Zeng Z
    Mol Cancer; 2021 Jan; 20(1):7. PubMed ID: 33397409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer.
    Sun Q; Zou X; Zhang T; Shen J; Yin Y; Xiang J
    Gynecol Oncol; 2014 Mar; 132(3):730-8. PubMed ID: 24503464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting vasculogenic mimicry by phytochemicals: A potential opportunity for cancer therapy.
    Haiaty S; Rashidi MR; Akbarzadeh M; Maroufi NF; Yousefi B; Nouri M
    IUBMB Life; 2020 May; 72(5):825-841. PubMed ID: 32026601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment.
    Li S; Meng W; Guan Z; Guo Y; Han X
    Biomed Pharmacother; 2016 May; 80():127-135. PubMed ID: 27133049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells.
    Lee CH; Wu YT; Hsieh HC; Yu Y; Yu AL; Chang WW
    Biochimie; 2014 Sep; 104():117-26. PubMed ID: 24950183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors.
    Sun B; Zhang D; Zhao N; Zhao X
    Oncotarget; 2017 May; 8(18):30502-30510. PubMed ID: 27034014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.